Recently, a pilot trial (ClinicalTrials.gov identifier: NCT00107211) has seen 38 patients with in situ Her2-expressing ductal carcinoma (DCIS) being vaccinated one month before lumpectomy with autologous DC that were pulsed with six HLA class II promiscuous-binding peptides from Her2 (DC1 vaccine) [70]. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.